

EDITORIAL

The Promised Land

Cancer Gene Therapy (2013) **20**, 651; doi:10.1038/cgt.2013.73

'This is the land of which I swore to give Abraham, Isaac, and Jacob, saying, 'I will give it to your descendants.' I have caused you to see it with your eyes, but you shall not cross over there.'

Deuteronomy

It has been nearly 20 years since the first issue of *Cancer Gene Therapy* was published. Its founding mission was to foster the development of this promising form of cancer treatment that it may help patients with this disease.

We had hoped during our tenure as the Journal's Editors, to proclaim here that worldwide regulatory approvals for these treatments had been attained. This distinction will now fall to our successor Editor.

We wish to thank the many contributors to the Journal that we were privileged to serve. Their efforts have taken us to the mountain top and we have seen there the promise and potential of gene therapy technology.

We are honored to return to their ranks and contribute along with them so we may reach the Promised Land.

RE Sobol and KJ Scanlon
E-mail: rsobol@naturecgt.com